DAWN (Day One Biopharmaceuticals) Current Accrued Expense: $53.9 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DAWN Day One Biopharmaceuticals Inc DAWN
12 GF Score
Price $21.53
! 5 Warning Signs
View Full Analysis

What is Day One Biopharmaceuticals Current Accrued Expense?

Day One Biopharmaceuticals DAWN 12 Current Accrued Expense is $53.9 Mil as of Dec. 2025. GuruFocus rates DAWN with a GF Score™ of 12/100. The stock has 5 warning signs investors should review.

Day One Biopharmaceuticals's Current Accrued Expense for the quarter that ended in Dec. 2025 was $53.9 Mil.

Day One Biopharmaceuticals's quarterly Current Accrued Expense increased from Jun. 2025 ($42.0 Mil) to Sep. 2025 ($44.8 Mil) and increased from Sep. 2025 ($44.8 Mil) to Dec. 2025 ($53.9 Mil).

Day One Biopharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 ($25.5 Mil) to Dec. 2024 ($62.4 Mil) but then declined from Dec. 2024 ($62.4 Mil) to Dec. 2025 ($53.9 Mil).

Day One Biopharmaceuticals Current Accrued Expense Related Terms

Day One Biopharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Day One Biopharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Day One Biopharmaceuticals Current Accrued Expense Chart

Day One Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 6.61 15.77 25.48 62.42 53.94

Day One Biopharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.42 35.61 42.00 44.82 53.94
DAWN
12GF Score
Day One Biopharmaceuticals Inc DAWN
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Day One Biopharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $53.9 Mil mean?
Day One Biopharmaceuticals (DAWN) has a Current Accrued Expense of $53.9 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on Day One Biopharmaceuticals and its competitors.
Is Day One Biopharmaceuticals' Current Accrued Expense too high?
Day One Biopharmaceuticals' current Current Accrued Expense is $53.9 Mil. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' Current Accrued Expense compare to TYRA and DFTX?
Day One Biopharmaceuticals' Current Accrued Expense of $53.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Day One Biopharmaceuticals and its competitors. Day One Biopharmaceuticals's current Current Accrued Expense is $53.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current Current Accrued Expense of $53.9 Mil. The current Current Accrued Expense is $53.9 Mil. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current Current Accrued Expense is $53.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Day One Biopharmaceuticals Business Description

Address 1800 Sierra Point Parkway, Suite 200, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score

Get the complete analysis for DAWN

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.53
Price